Jazz Pharmaceuticals (JAZZ) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $15.18B, a trailing price-to-earnings ratio of 16.0 and a free-cash-flow yield of 8.0%. Over the most recent reported fiscal year, revenue grew 4.9% and free cash flow per share fell 8.0%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Buy · 6.0/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Rising · +20.6% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-13.6%
How far the last close sits under the highest price of the past five years.
Market cap
$15.18B
Trailing P/E
16.0
Price / book
3.6
Price / sales
3.2
FCF yield
8.0%
Dividend yield
—
Gross margin
89.1%
Operating margin
24.0%
Net margin
4.4%
Revenue growth (YoY)
+4.9%
Revenue growth (3-yr annual)
+5.3%
EPS growth (YoY)
-61.3%
FCF/share growth (YoY)
-8.0%
Beta
0.4
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
JAZZ earnings
Next report: Feb 23, 2027 (Q4 2026, EPS estimate $6.66).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 2, 2026
-$3.88
-$2.38
-63.0%
$1.24B
Q2 2026
Aug 3, 2026
$5.71
$6.18
-7.6%
$1.21B
Q1 2026
May 5, 2026
$6.34
$4.66
+36.0%
$1.07B
Q4 2025
Feb 24, 2026
$6.64
$6.51
+2.0%
$1.20B
JAZZ analyst price target
Median target $300.00 from 22 analysts, ranging $220.00 – $330.00.
Nama's AI scorecard currently rates Jazz Pharmaceuticals Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals trades at a trailing price-to-earnings ratio of 16.0.
When does JAZZ report earnings?
Jazz Pharmaceuticals's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $6.66.
What is the JAZZ price target?
The median analyst price target from 22 analysts is $300.00, with a range of $220.00 – $330.00.
Is JAZZ Shariah compliant?
Nama's AAOIFI-style screen reads Jazz Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.